The FDA’s recommendations to improve diversity in clinical trials provide a much-needed action plan to jumpstart the changes that need to be made to ensure inclusive care, yet these recommended guidelines only scratch the surface of ideal action in clinical trials....
Educating future and current scientists from diverse backgrounds benefits the entire biomedical research enterprise, changing the world through advances in disease diagnosis, treatment, and prevention....
Promoting a diverse clinical trial workforce is a key pillar of any effective effort to promote patient population diversity....
Patient-driven consent-management tools and granular data segmentation need to be balanced for health equity, patient privacy and interoperability....
The clinical trial industry must be proactive and transparent in its communications with underserved communities with less access to healthcare resources and a wariness about participating in medical research....
We need to widen the data net and do a better job of analyzing those data to identify clinical trials participants from previously ignored patient populations....
Obstacles exist, but the clinical trials sector can make small changes to make transgender, nonbinary individuals feel safe to join studies....
The challenges of the pandemic may have given the clinical research profession the gift of perspective that will positively affect the outlook on our industry’s collective future....
Although many clinical trial sponsors are broadly aware of the need for more diverse participation, most still struggle to implement specific, structural changes that will help trials better represent the wider population....
Clinical trials largely fail to enroll diverse patient populations — and in the last couple of years, patient advocates, the FDA and even a slate of pharma companies have taken steps to change that....
